Treatment Approaches for Prolactinomas in Postmenopausal Women: Retrospective Analysis
Overview
This retrospective study analyzed 104 postmenopausal women with prolactinomas, focusing on dopamine agonist (DA) withdrawal outcomes in those diagnosed before menopause and clinical features of postmenopausal-diagnosed cases. The study provides insights into bromocriptine treatment efficacy and remission rates after DA discontinuation in this population.
Background
Prolactinomas are the most common pituitary adenomas, predominantly affecting women of reproductive age, with clinical manifestations such as amenorrhea and galactorrhea. Dopamine agonists like cabergoline and bromocriptine are first-line treatments. Menopause may positively influence disease course, potentially allowing some patients to maintain remission after DA withdrawal. However, data on postmenopausal prolactinoma management, especially involving bromocriptine, remain limited.
Data Highlights
The study included 104 postmenopausal women with prolactinomas treated between 2014 and 2024. Patients were divided into premenopausal-diagnosed (n=53) and postmenopausal-diagnosed groups. Biochemical remission was defined as sustained serum prolactin < 25 ng/mL for ≥ 24 months. Statistical analyses were performed to compare hormone levels, tumor size, and treatment outcomes between groups.
Key Findings
Among premenopausal-diagnosed patients, bromocriptine withdrawal was attempted in a subset with biochemical remission, assessing recurrence rates post-menopause.
Menopause was associated with stabilization or reduction in prolactin levels and tumor size in many patients continuing DA therapy.
Postmenopausal-diagnosed patients often presented with incidental findings due to lack of overt symptoms, highlighting underdiagnosis in this population.
Bromocriptine was the primary DA used, providing valuable data on its efficacy and safety in postmenopausal women.
The study supports the feasibility of DA withdrawal in selected postmenopausal patients with sustained remission, but emphasizes the need for individualized monitoring.
Clinical Implications
Clinicians should consider the potential for remission and safe withdrawal of dopamine agonists in postmenopausal women with prolactinomas, especially those diagnosed before menopause who have achieved biochemical remission. Continuous monitoring of prolactin levels and tumor size remains essential to detect recurrence early. Bromocriptine remains a viable treatment option in this demographic, with withdrawal decisions tailored to individual patient stability.
Conclusion
This study enhances understanding of prolactinoma management in postmenopausal women, demonstrating that bromocriptine withdrawal can be successful in selected cases and that menopause may favorably impact disease course. Further prospective studies are needed to optimize treatment protocols in this population.
Related Resources & Content
Melmed et al. 2011 -- Diagnosis and Treatment of Hyperprolactinemia
